Unlock instant, AI-driven research and patent intelligence for your innovation.

Heterocyclic compounds for medical treatment

A compound, the technology of pharmacy, used in the field of heterocyclic compounds for drug therapy

Pending Publication Date: 2021-10-26
C4 THERAPEUTICS INC
View PDF67 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thalidomide-cereblon binding in vivo may be responsible for teratogenicity of thalidomide, study suggests

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heterocyclic compounds for medical treatment
  • Heterocyclic compounds for medical treatment
  • Heterocyclic compounds for medical treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0466] The present invention also provides the following enumerated embodiment (E):

[0467] E1: In one embodiment, the present invention provides a compound of formula XIV or a pharmaceutically acceptable salt thereof according to A1, wherein Z is selected from the group consisting of:

[0468] i) covalent bonds,

[0469] ii) carbonyl,

[0470] iii)-NR 1 -,

[0471] iv) -O-CH 2 -C(=O)-NR 1 -,

[0472] v)-C(=O)-NR 1 -,and

[0473] vi)-NR 1 -C(=O)-.

[0474] E2: In one embodiment, the present invention provides a compound of formula XIV according to any one of A1 or E1, or a pharmaceutically acceptable salt thereof, wherein R 1 for hydrogen.

[0475] E3: In one embodiment, the present invention provides a compound of formula XIV or a pharmaceutically acceptable salt thereof according to any one of A1 and E1 to E2, wherein each R 2 for-C 1-6 Alkyl or -N(R 5 , R 6 ).

[0476] E4: In one aspect, the present invention provides a compound of formula XIV or a pharmace...

Embodiment A

[0969] Tablets of the following composition are prepared in the usual way:

[0970]

[0971]

[0972] Table 1: Possible tablet compositions

[0973] preparation steps

[0974] 1. Mix ingredients 1, 2, 3 and 4 and granulate with purified water.

[0975] 2. Dry the granules at 50°C.

[0976] 3. Pass the granules through suitable milling equipment.

[0977] 4. Add ingredient 5 and stir for three minutes; compress on a suitable tablet machine.

Embodiment B-1

[0979] Prepare capsules of the following composition:

[0980]

[0981] Table 2: Possible Capsule Composition

[0982] preparation steps

[0983] 1. Mix ingredients 1, 2 and 3 in a suitable mixer for 30 minutes.

[0984] 2. Add ingredients 4 and 5 and mix for 3 minutes.

[0985] 3. Fill into suitable capsules.

[0986] The compound of formula XIV, lactose and cornstarch are mixed first in a mixer and then in a pulverizer. The mixture is returned to the mixer; add the talc and mix thoroughly. The mixture is machine filled into suitable capsules, such as hard gelatin capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides heterocyclic compounds that bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation in a human or other host. The present invention also provides compounds that can be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 814,706, filed March 6, 2019. The entire content of this application is incorporated herein by reference. technical field [0003] The present invention provides compounds that bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN), which can alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in the breakdown of intrinsic downstream proteins that mediate disease. The present invention also provides compounds useful as synthetic intermediates for the preparation of bifunctional compounds for targeted protein degradation. Accordingly, the compounds of the invention are useful in the treatment or prevention of abnormal cell proliferation, including tumors and cancers. Background technique [0004] Protein degradation is a highly regulated and essential process for maintaining cellular homeostasis. S...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D401/04A61K31/335
CPCC07D263/58C07D405/12C07D277/68C07D403/04C07D417/04C07D413/04C07D209/34C07D413/12C07D413/06C07D471/04C07D417/06C07D498/04C07D413/14A61P35/00
Inventor C·G·纳斯维舒克R·诺克罗斯F·戴伊A·古尔吉勒尔E·A·库斯尼尔
Owner C4 THERAPEUTICS INC